5-MeO-MPMI explained

5-MeO-MPMI (also known as 5-Methoxy-N-methyl-(α,N-trimethylene)tryptamine) is a tryptamine derivative that is a psychedelic drug. It was first developed by the team led by JE Macor in 1992,^[1] and subsequently investigated by the team led by David Nichols from Purdue University in the late 1990s. This compound produces psychedelic-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active.^[2]

See also

• 5-MeO-pyr-T
• 5F-MPMI
• 4-HO-MPMI
• 4-HO-pyr-T
• CP-135,807
• MPMI

Notes and References

1. 10.1021/jm00101a032 . Macor JE, Blake J, Fox CB, Johnson C, Koe BK, Lebel LA, Morrone JM, Ryan K, Schmidt AW, Schulz DW . Koe BK. Synthesis and serotonergic pharmacology of the enantiomers of 3-[(N-methylpyrrolidin-2-yl)methyl]-5-methoxy-1H-indole: discovery of stereogenic differentiation in the aminoethyl side chain of the neurotransmitter serotonin . Journal of Medicinal Chemistry . 1992 . 35 . 23 . 4503–5. 1447752. etal.
2. 10.1021/jm990325u . Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE . Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain . Journal of Medicinal Chemistry . 1999 . 42 . 20 . 4257–4263 . 10514296. 10.1.1.690.4941 .